NASDAQ:CERSCerus Stock Price, Forecast & News

Cerus' stock was trading at $4.76 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CERS stock has increased by 48.1% and is now trading at $7.05.
View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cerus.

Cerus is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Cerus.

Cerus Co. (NASDAQ:CERS) released its quarterly earnings data on Tuesday, August, 4th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. Cerus had a negative net margin of 83.78% and a negative return on equity of 76.83%.
View Cerus' earnings history.

Cerus updated its FY 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $89-93 million, compared to the consensus revenue estimate of $112.8 million.

4 equities research analysts have issued 12 month target prices for Cerus' stock. Their forecasts range from $6.50 to $9.00. On average, they expect Cerus' stock price to reach $7.63 in the next year. This suggests a possible upside of 8.2% from the stock's current price.
View analysts' price targets for Cerus.

Media stories about CERS stock have trended very positive on Monday, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cerus earned a news impact score of 3.2 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Cerus.

Some companies that are related to Cerus include Align Technology (ALGN), West Pharmaceutical Services (WST), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), Neogen (NEOG), Haemonetics (HAE), ICU Medical (ICUI), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), OraSure Technologies (OSUR), Meridian Bioscience (VIVO), Antares Pharma (ATRS) and Anika Therapeutics (ANIK).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Immunomedics (IMMU), Opko Health (OPK), Grayscale Bitcoin Trust (Btc) (GBTC), ACADIA Pharmaceuticals (ACAD), Aduro BioTech (ADRO) and Celldex Therapeutics (CLDX).

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Cerus' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (6.54%), Paradigm Capital Management Inc. NY (0.92%), Peregrine Capital Management LLC (0.88%), Raymond James & Associates (0.73%), UBS Group AG (0.26%) and Swiss National Bank (0.22%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, Timothy L Moore and William Mariner Greenman.
View institutional ownership trends for Cerus.

CERS stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Paradigm Capital Management Inc. NY, Lesa Sroufe & Co, Premier Asset Management LLC, Raymond James & Associates, Personal CFO Solutions LLC, Leap Investments LP, and Shufro Rose & Co. LLC. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, and William Mariner Greenman.
View insider buying and selling activity for Cerus.

CERS stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG, Sumitomo Mitsui Trust Holdings Inc., Swiss National Bank, Raymond James Financial Services Advisors Inc., Trexquant Investment LP, New York State Common Retirement Fund, SG Americas Securities LLC, and Exchange Traded Concepts LLC. Company insiders that have bought Cerus stock in the last two years include Timothy L Moore, and William Mariner Greenman.
View insider buying and selling activity for Cerus.

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CERS stock can currently be purchased for approximately $7.05.

Cerus has a market capitalization of $1.17 billion and generates $74.65 million in revenue each year. The biotechnology company earns $-71,240,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Cerus employs 240 workers across the globe.

The official website for Cerus is www.cerus.com.

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]